SSY Group's vitamin B6 injection passes key evaluation in China

SSY Group Limited's board announced that China's National Medical Products Administration has approved the passing of Consistency Evaluation of the Quality and Efficacy of Generic Drugs for the group's Vitamin B6 Injection (1ml:0.1g). This marks a crucial step in the product's regulatory journey within China.

The Vitamin B6 Injection is primarily utilized for the prevention and treatment of vitamin B6 deficiency. Additionally, it finds application in addressing vomiting induced by pregnancy, radiation sickness, and anticancer drugs, as well as managing seborrheic dermatitis and neonatal hereditary vitamin B6 dependence syndrome.

This voluntary announcement aims to keep shareholders and potential investors informed about the latest business developments within the group. The board comprises a mix of executive, non-executive, and independent non-executive directors, led by executive director and company secretary Chow Hing Yeung.